Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Binod Dhakal et al.|New England Journal of Medicine|2023Cited by 719
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengaß, Suzanne Lentzsch, Elena Zamagni et al.|The Lancet Oncology|2019Cited by 493
CD38 antibodies in multiple myeloma: back to the futureNiels W.C.J. van de Donk, Fabio Malavasi|Blood|2017Cited by 482
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaInger S. Nijhof, Niels W.C.J. van de Donk|Blood|2016Cited by 377
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumabInger S. Nijhof, Niels W.C.J. van de Donk|Leukemia|2015Cited by 266